Akero Therapeutics Inc AKRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKRO is a good fit for your portfolio.
News
-
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
-
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
-
AKRO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges Akero Therapeutics, Inc. Investors with Losses to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lincoln, Compass Minerals, Exscientia, and Akero and Encourages Investors to Contact the Firm
-
AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
-
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
-
Robbins LLP Reminds Investors of AKRO of the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class Action
Trading Information
- Previous Close Price
- $20.73
- Day Range
- $19.76–20.82
- 52-Week Range
- $11.25–58.38
- Bid/Ask
- $19.92 / $20.75
- Market Cap
- $1.38 Bil
- Volume/Avg
- 457,666 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 58
- Website
- https://www.akerotx.com
Comparables
Valuation
Metric
|
AKRO
|
CBAY
|
PLRX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.63 | 12.65 | 2.11 |
Price/Sales | — | 111.01 | 3,678.63 |
Price/Cash Flow | — | — | — |
Price/Earnings
AKRO
CBAY
PLRX
Financial Strength
Metric
|
AKRO
|
CBAY
|
PLRX
|
---|---|---|---|
Quick Ratio | 29.86 | 10.70 | 15.95 |
Current Ratio | 30.12 | 10.96 | 16.12 |
Interest Coverage | −57.10 | −5.27 | −138.69 |
Quick Ratio
AKRO
CBAY
PLRX
Profitability
Metric
|
AKRO
|
CBAY
|
PLRX
|
---|---|---|---|
Return on Assets (Normalized) | −24.65% | −30.06% | −23.39% |
Return on Equity (Normalized) | −26.81% | −51.97% | −25.61% |
Return on Invested Capital (Normalized) | −30.22% | −30.87% | −29.08% |
Return on Assets
AKRO
CBAY
PLRX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gqwwmbvlq | Yffq | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Plvbnjkq | Cgytls | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fvkjpxb | Jknwhd | $108.2 Bil | |
MRNA
| Moderna Inc | Kgqtcqrvq | Mwxn | $50.9 Bil | |
ARGX
| argenx SE ADR | Sdqyttdbs | Vbz | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Qttltvt | Wld | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hdcrqsz | Myfgr | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pygpcss | Vbhyl | $14.6 Bil | |
INCY
| Incyte Corp | Yjhyjmcb | Ynmsff | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Splfsrtzdc | Ffmfnv | $12.3 Bil |